Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome

Journal of Investigative Dermatology

Volumn 135, Issue 8, 2015, Pages 2084-2092

  Wong, Henry K ^a,b   Gibson, Heather ^a,b   Hake, Timothy ^a,b   Geyer, Susan ^a,b   Frederickson, Julie ^a   Marcucci, Guido ^a,b   Caligiuri, Michael A ^a,b   Porcu, Pierluigi ^a,b   Mishra, Anjali ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; LUCIFERASE; MESSENGER RNA; PLS3 PROTEIN; PROTEIN; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; GATA6 PROTEIN, HUMAN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PLASTIN; TWIST1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; JURKAT CELL LINE; LYMPHOCYTE; MALE; MIDDLE AGED; MONONUCLEAR CELL; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PSORIASIS; PYROSEQUENCING; SEZARY SYNDROME; UPREGULATION; CASE CONTROL STUDY; CELL LINE; DRUG EFFECTS; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN TUMOR;

AGED; AZACITIDINE; CASE-CONTROL STUDIES; CELL LINE; DNA METHYLATION; FEMALE; FIBROBLASTS; GATA6 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; JURKAT CELLS; LYMPHOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MICROFILAMENT PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SEZARY SYNDROME; SKIN NEOPLASMS; TWIST TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84937634087     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.116     Document Type: Article

References (38)

1. Agar NS, Wedgeworth E, Crichton S et al. (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28:4730-9
2. Arpin M, Friederich E, Algrain M et al. (1994) Functional differences between Land T-plastin isoforms. J Cell Biol 127:1995-2008
3. Begue E, Jean-Louis F, Bagot M et al. (2012) Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma. Blood 120:143-54
4. Caprini E, Cristofoletti C, Arcelli D et al. (2009) Identification of key regions and genes important in the pathogenesis of Sezary Syndrome by combining genomic and expression microarrays. Cancer Res 69:8438-46
5. De S, Shaknovich R, Riester M et al. (2013) Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet 9:e1003137
6. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21:5400-13
7. Feinberg AP (2005) Cancer epigenetics is no Mickey Mouse. Cancer Cell 8: 267-8
8. Gallardo F, Esteller M, Pujol RM et al. (2004) Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. Haematologica 89:1401-3
9. Gaudet F, Hodgson JG, Eden A et al. (2003) Induction of tumors in mice by genomic hypomethylation. Science 300:489-92
10. Gronbaek K, Hother C, Jones PA (2007) Epigenetic changes in cancer. Apmis 115:1039-59
11. Jones CL, Ferreira S, McKenzie RC et al. (2012) Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma. J Invest Dermatol 132:2042-9
12. Kaltoft K, Bisballe S, Rasmussen HF et al. (1987) A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 279:293-8
13. Karenko L, Hahtola S, Ranki A (2007) Molecular cytogenetics in the study of cutaneous T-cell lymphomas (CTCL). Cytogenet Genome Res 118: 353-61
14. Klemke C-D, Brade J, Weckesser S et al. (2008) The diagnosis of Sezary syndrome on peripheral blood by flow cytometry requires the use of multiple markers. Br J Dermatol 159:871-80
15. Li B, Zheng YW, Sano Y et al. (2011) Evidence for mesenchymal-epithelial transition associated with mouse hepatic stem cell differentiation. PLoS One 6:e17092
16. Lin CS, Lau A, Huynh T et al. (1999) Differential regulation of human T-plastin gene in leukocytes and non-leukocytes: identification of the promoter, enhancer, and CpG island. DNA Cell Biol 18:27-37
17. McKenzie RC, Jones CL, Tosi I et al. (2012) Constitutive activation of STAT3 in Sezary syndrome is independent of SHP-1. Leukemia 26:323-31
18. Mi S, Roberts RJ (1992) How M.MspI and M.HpaII decide which base to methylate. Nucleic Acids Res 20:4811-6
19. Mishra A, Porcu P (2011) Early CTCL diagnosis, a (miR)age no more? Blood 118: 5717-8
20. Narducci MG, Arcelli D, Picchio MC et al. (2011) MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2:e151
21. Nebozhyn M, Loboda A, Kari L et al. (2006a) Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 107:3189-96
22. Nebozhyn M, Loboda A, Kari L et al. (2006b) Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy 10.1182/blood-2005-07-2813. Blood 107: 3189-96
23. Olsen EA, Whittaker S, Kim YH et al. (2011) Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29:2598-607
24. Pham D, Vincentz JW, Firulli AB et al. (2012) Twist1 regulates Ifng expression in Th1 cells by interfering with Runx3 function. J Immunol 189:832-40
25. Prince HM, Whittaker S, Hoppe RT (2009) How I treat mycosis fungoides and Sezary syndrome. Blood 114:4337-53
26. Puisieux A, Valsesia-Wittmann S, Ansieau S (2006) A twist for survival and cancer progression. Br J Cancer 94:13-7
27. Qin Q, Xu Y, He T et al. (2012) Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res 22:90-106
28. Ralfkiaer U, Hagedorn PH, Bangsgaard N et al. (2011) Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 118:5891-900
29. Rodriguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17:330-9
30. Shimizu R, Yamamoto M (2005) Gene expression regulation and domain function of hematopoietic GATA factors. Semin Cell Dev Biol 16:129-36
31. Shinomiya H (2012) Plastin family of actin-bundling proteins: its functions in leukocytes, neurons, intestines, and cancer. Int J Cell Biol 2012:213492
32. Tang N, Gibson H, Germeroth T et al. (2010) T-plastin (PLS3) gene expression differentiates Sezary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. Br J Dermatol 162:463-6
33. van Doorn R, Dijkman R, Vermeer MH et al. (2004) Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary Syndrome identified by gene expression analysis. Cancer Res 64:5578-86
34. van Doorn R, Zoutman WH, Dijkman R et al. (2005) Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23: 3886-96
35. Vermeer MH, van Doorn R, Dijkman R et al. (2008) Novel and highly recurrent chromosomal alterations in Sezary Syndrome. Cancer Res 68: 2689-98
36. Wong HK, Mishra A, Hake T et al. (2011) Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary Syndrome). Br J Haematol 155:150-66
37. Zhang Q, Raghunath PN, Vonderheid E et al. (2000) Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 157:1137-46
38. Zhong Y, Wang Z, Fu B et al. (2011) GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS One 6:e22129